Enzo Biochem (ENZ) Competitors $1.14 0.00 (0.00%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ENZ vs. SERA, LFMD, BDSX, ATPC, PIII, CORBF, QIPT, EUDA, MGRX, and XGNShould you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Sera Prognostics (SERA), LifeMD (LFMD), Biodesix (BDSX), Agape ATP (ATPC), P3 Health Partners (PIII), Global Cord Blood (CORBF), Quipt Home Medical (QIPT), EUDA Health (EUDA), Mangoceuticals (MGRX), and Exagen (XGN). These companies are all part of the "healthcare" industry. Enzo Biochem vs. Sera Prognostics LifeMD Biodesix Agape ATP P3 Health Partners Global Cord Blood Quipt Home Medical EUDA Health Mangoceuticals Exagen Sera Prognostics (NASDAQ:SERA) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Is SERA or ENZ more profitable? Enzo Biochem has a net margin of 134.17% compared to Sera Prognostics' net margin of 0.00%. Enzo Biochem's return on equity of -21.50% beat Sera Prognostics' return on equity.Company Net Margins Return on Equity Return on Assets Sera PrognosticsN/A -46.71% -35.01% Enzo Biochem 134.17%-21.50%-14.95% Do insiders & institutionals believe in SERA or ENZ? 54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by insiders. Comparatively, 15.5% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, SERA or ENZ? Enzo Biochem has higher revenue and earnings than Sera Prognostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$107K2,398.20-$36.24M-$0.98-7.85Enzo Biochem$33.34M1.77$20.29MN/AN/A Do analysts recommend SERA or ENZ? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community prefer SERA or ENZ? Enzo Biochem received 202 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 55.64% of users gave Enzo Biochem an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformSera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Enzo BiochemOutperform Votes21255.64% Underperform Votes16944.36% Does the media favor SERA or ENZ? In the previous week, Enzo Biochem had 6 more articles in the media than Sera Prognostics. MarketBeat recorded 8 mentions for Enzo Biochem and 2 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.47 beat Enzo Biochem's score of 0.34 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enzo Biochem 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, SERA or ENZ? Sera Prognostics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. SummaryEnzo Biochem beats Sera Prognostics on 8 of the 14 factors compared between the two stocks. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Get Enzo Biochem News Delivered to You Automatically Sign up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENZ vs. The Competition Export to ExcelMetricEnzo BiochemMedical laboratories IndustryMedical SectorNYSE ExchangeMarket Cap$58.92M$2.47B$5.36B$19.17BDividend YieldN/A1.67%5.22%3.52%P/E RatioN/A33.47131.9331.74Price / Sales1.77235.371,440.1517.87Price / CashN/A507.7939.0620.46Price / Book0.724.674.745.38Net Income$20.29M-$31.39M$115.43M$984.37M7 Day Performance-1.29%-1.01%-0.86%-0.54%1 Month Performance2.23%-3.75%3.61%-0.97%1 Year Performance-14.55%43.32%38.90%29.31% Enzo Biochem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENZEnzo Biochem0.5499 of 5 stars$1.15flatN/A-17.7%$58.92M$33.34M0.00520Dividend AnnouncementAnalyst ForecastNews CoverageSERASera Prognostics0.2864 of 5 stars$6.70-3.7%N/A+370.5%$223.58M$310,000.00-6.84120News CoverageGap DownLFMDLifeMD2.153 of 5 stars$4.43+3.3%$12.00+170.9%-33.0%$184.98M$178.28M-6.33230Upcoming EarningsShort Interest ↑News CoverageBDSXBiodesix3.3011 of 5 stars$1.60-2.7%$3.06+91.8%+12.2%$182.92M$60.90M-3.47220Upcoming EarningsATPCAgape ATP0.3978 of 5 stars$1.88-4.1%N/A-88.3%$144.71M$1.38M-3.1340Positive NewsGap UpHigh Trading VolumePIIIP3 Health Partners3.1221 of 5 stars$0.44+8.2%$4.50+924.1%-73.8%$138.90M$1.40B-0.68500Positive NewsCORBFGlobal Cord BloodN/A$1.00-20.0%N/A+0.0%$121.55M$196.12M0.001,202Negative NewsGap DownQIPTQuipt Home Medical2.8664 of 5 stars$2.76+1.8%$6.25+126.4%-41.7%$117.50M$255.81M-25.091,200News CoverageEUDAEUDA Health1.5152 of 5 stars$4.75+1.1%N/A+508.3%$116.98M$3.71M0.002Positive NewsMGRXMangoceuticals1.601 of 5 stars$2.44+0.8%N/A-98.5%$60.56M$866,792.00-0.383Upcoming EarningsXGNExagen4.4687 of 5 stars$2.71+0.7%$7.00+158.3%+51.2%$47.13M$52.55M-2.79220 Related Companies and Tools Related Companies Sera Prognostics Competitors LifeMD Competitors Biodesix Competitors Agape ATP Competitors P3 Health Partners Competitors Global Cord Blood Competitors Quipt Home Medical Competitors EUDA Health Competitors Mangoceuticals Competitors Exagen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ENZ) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzo Biochem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzo Biochem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.